Tyrosine Kinase Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Global Tyrosine Kinase Inhibitors Market is segmented by Type (BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, BRAF Kinase Inhibitors, ROS1 Inhibitors, and Other Types), Application (Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The report offers the value (in USD million) for the above segments.

Tyrosine Kinase Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Tyrosine Kinase Inhibitors Market Size

Tyrosine Kinase Inhibitors Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 67.33 Billion
Market Size (2030) USD 100.64 Billion
CAGR (2025 - 2030) 8.37 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Tyrosine Kinase Inhibitors Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Tyrosine Kinase Inhibitors Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Tyrosine Kinase Inhibitors Market Analysis

The Tyrosine Kinase Inhibitors Market size is estimated at USD 67.33 billion in 2025, and is expected to reach USD 100.64 billion by 2030, at a CAGR of 8.37% during the forecast period (2025-2030).

The COVID-19 pandemic affected healthcare systems around the world and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks during the early pandemic phase. However, as the pandemic progressed, kinase inhibitors, particularly tyrosine kinase inhibitors (TKIs), started to show promising results in COVID-19 patients, and there was an increased number of clinical trials. For instance, according to an article published by Frontiers in April 2022, imatinib, an enzyme inhibitor and small molecule kinase inhibitor tyrosine kinase inhibitor drug, successfully inhibited cellular tyrosine kinase as well as viral fusion, blocking the COVID-19 virus replication. The source also stated that there were three clinical trials that were underway in different parts of the world to investigate the clinical efficacy of imatinib on COVID-19 patients. Thus, the pandemic had a significant impact on the market growth; however, as the pandemic has subsided currently, the studied market is expected to have stable growth during the forecast period of the study.

Factors such as the increasing prevalence of cancer, growing research activities, and investment in precision oncology and targeted cancer therapy are expected to enhance market growth.

The rising prevalence of cancer is a major factor driving the market growth. For instance, as per the report published by the Chinese Medical Journal in March 2022, China is experiencing a greater incidence of cancers. In 2022, there were approximately 4,820,000 new cancer cases in China, in which the most common is lung cancer.

Moreover, according to the data published by National Cancer Center Japan in June 2022, an estimated 1,019,000 new cases of cancer were expected in Japan in 2022, out of which 158,200 were new cases of colon/rectum cancer, 132,100 cases of stomach cancer, 128,800 cases of lung/trachea cancer, 96,400 cases of prostate cancer, and 95,000 cases of breast cancer. Thus, the greater incidence of cancers has increased the demand for various tyrosine kinase inhibitor drugs and other cancer treatment drugs for the treatment of cancers, contributing to the growth of the cancer drug market.

Furthermore, the growing research and development activities for molecular targeted therapies, including signal transduction inhibitors such as tyrosine kinase inhibitors, are also expected to boost the market growth. For instance, in August 2022, Theseus Pharmaceuticals, Inc. announced business and pipeline highlights that were focused on developing next-generation protein kinase inhibitors and small molecule kinase inhibitors to outsmart cancer resistance. The company invested USD 7.3 million in the second quarter of 2022, as compared to USD 4.5 million for the same period in 2021. Thus, the growing research activities along with the increasing investments in kinase inhibitors are expected to enhance the market growth.

Additionally, the rising developments by major market players are also expected to enhance market growth. For instance, in March 2021, Pfizer Inc. received United States FDA approval for a supplemental New Drug Application (sNDA) for LORBRENA (lorlatinib), a tyrosine kinase inhibitor, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). LORBRENA is indicated for adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test, contributing to the growth of the anaplastic lymphoma kinase inhibitors market and strengthening the receptor tyrosine kinase inhibitors segment.

Thus, the aforementioned factors such as the rising prevalence of cancer, increasing research and development for novel targeted cancer drugs like tyrosine kinase inhibitors, and the rising developments by key market players are expected to enhance the market growth. However, the high cost of therapy is expected to hinder market growth.

Tyrosine Kinase Inhibitors Industry Overview

The tyrosine kinase inhibitors market is moderately fragmented. The global key players are manufacturing the majority of the tyrosine kinase inhibitor therapies. Market leaders with more funds for research and a better distribution system have established their position in the kinase inhibitors arena. Moreover, Asia-Pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market grow at a significant rate. Some of the market players include Bayer, Boehringer Ingelheim International, F. Hoffmann-La Roche Ltd, AstraZeneca PLC, and Novartis.

Tyrosine Kinase Inhibitors Market Leaders

  1. Boehringer Ingelheim International

  2. F. Hoffmann-La Roche

  3. AstraZeneca plc

  4. Novartis AG

  5. Bayer AG

  6. *Disclaimer: Major Players sorted in no particular order
Tyrosine Kinase Inhibitors Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Tyrosine Kinase Inhibitors Market News

  • In June 2022, The European Commission approved capmatinib (Tabrecta), a tyrosine kinase inhibitor, as a single agent for the treatment of patients with MET exon14 skipping (METex14) altered advanced non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
  • In February 2022, Merck announced that the European Commission (EC) has approved once-daily oral TEPMETKO (tepotinib), a tyrosine kinase inhibitor, as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC).

Tyrosine Kinase Inhibitors Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cancer
    • 4.2.2 Growing Research Activities and Investment in Tyrosine Kinase Inhibitors
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Therapy
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Type
    • 5.1.1 BCR-ABL Tyrosine Kinase Inhibitor
    • 5.1.2 Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
    • 5.1.3 Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
    • 5.1.4 Other Types
  • 5.2 By Application
    • 5.2.1 Chronic Myeloid Leukemia (CML)
    • 5.2.2 Lung Cancer
    • 5.2.3 Breast Cancer
    • 5.2.4 Renal Cell Cancer
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca PLC
    • 6.1.2 Bayer AG
    • 6.1.3 Boehringer Ingelheim International
    • 6.1.4 Bristol-Myers Squibb Company
    • 6.1.5 Eisai Co. Ltd
    • 6.1.6 F. Hoffmann-La Roche Ltd
    • 6.1.7 Johnson and Johnson
    • 6.1.8 Novartis AG
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Eli Lilly and Company
    • 6.1.11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • 6.1.12 Spectrum Pharmaceuticals , Inc.
    • 6.1.13 Takeda Pharmaceutical Company Limited
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Tyrosine Kinase Inhibitors Industry Segmentation

As per the scope of the report, a tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades. The Tyrosine Kinase Inhibitors Market is segmented by Type (BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, BRAF Kinase Inhibitors, ROS1 Inhibitors, and Other Types), Application (Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Type BCR-ABL Tyrosine Kinase Inhibitor
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors
Other Types
By Application Chronic Myeloid Leukemia (CML)
Lung Cancer
Breast Cancer
Renal Cell Cancer
Other Applications
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Tyrosine Kinase Inhibitors Market Research FAQs

How big is the Tyrosine Kinase Inhibitors Market?

The Tyrosine Kinase Inhibitors Market size is expected to reach USD 67.33 billion in 2025 and grow at a CAGR of 8.37% to reach USD 100.64 billion by 2030.

What is the current Tyrosine Kinase Inhibitors Market size?

In 2025, the Tyrosine Kinase Inhibitors Market size is expected to reach USD 67.33 billion.

Who are the key players in Tyrosine Kinase Inhibitors Market?

Boehringer Ingelheim International, F. Hoffmann-La Roche, AstraZeneca plc, Novartis AG and Bayer AG are the major companies operating in the Tyrosine Kinase Inhibitors Market.

Which is the fastest growing region in Tyrosine Kinase Inhibitors Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Tyrosine Kinase Inhibitors Market?

In 2025, the North America accounts for the largest market share in Tyrosine Kinase Inhibitors Market.

What years does this Tyrosine Kinase Inhibitors Market cover, and what was the market size in 2024?

In 2024, the Tyrosine Kinase Inhibitors Market size was estimated at USD 61.69 billion. The report covers the Tyrosine Kinase Inhibitors Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Tyrosine Kinase Inhibitors Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Tyrosine Kinase Inhibitors Industry Report

The Global Tyrosine Kinase Inhibitors Market report provides a comprehensive industry analysis, covering various segments such as type and application across different geographies. The market forecast offers valuable insights into the industry outlook, including market growth and market trends that are expected to shape the future. The report highlights the market leaders and their contributions to the market value and market size. Additionally, the report includes a detailed market overview, market review, and market segmentation to help stakeholders understand the market dynamics.

Industry reports and industry research are essential for understanding the market data and market predictions. The industry statistics provided in the report offer a detailed look at the industry sales and industry trends, which are crucial for making informed business decisions. The market forecast and market outlook sections provide a clear picture of the expected growth rate and market growth, helping companies plan their strategies accordingly.

The report also includes a sample of the industry analysis as a free report PDF download, making it easier for research companies to access valuable information. The market report and market research sections offer insights into the market segmentation and market value, which are key to understanding the market's potential. The industry information and industry size sections provide a comprehensive view of the market, helping stakeholders make data-driven decisions.

Overall, the Global Tyrosine Kinase Inhibitors Market report is a valuable resource for anyone looking to understand the market trends, market data, and market predictions. The report example provided in the report PDF offers a clear understanding of the market dynamics, making it an essential tool for industry professionals.